SGK1 inhibitors

Thryv Licenses New SGK1 Inhibitors for Neurodegeneration

San Francisco, California, September 3, 2026 Thryv Therapeutics Inc., a clinical-stage biopharmaceutical company developing selective SGK1 inhibitors, has entered...

By cGxPwire Editor
September 7, 2026

We work Hard to get you posted with latest updates

Unwrap our new Directory

SGK1 inhibitors

Thryv Licenses New SGK1 Inhibitors for Neurodegeneration